Cooling Guidelines for Newborns Fall Short Across Europe, Landmark Audit Finds

Therapeutic hypothermia is one of the great success stories of modern neonatal medicine. By deliberately lowering the body temperature of newborns who have suffered oxygen deprivation around the time of birth, intensive care units can dramatically reduce both death and lifelong neurological disability in babies with moderate-to-severe hypoxic-ischaemic encephalopathy. Yet a new Europe-wide audit has delivered a sobering verdict: the clinical practice guidelines that are supposed to govern this life-saving therapy are, in most cases, not good enough to be applied safely without significant modification.

The study, published in The Lancet Regional Health – Europe and led by researchers from the Neonatal Critical Care Section of the European Society for Paediatric and Neonatal Intensive Care (ESPNIC), examined guidelines from eleven European countries: the United Kingdom, Italy, Spain, Switzerland, Germany, the Netherlands, France, Norway, Portugal, Slovakia and Turkey. A multidisciplinary panel of experienced clinicians independently scored each document using two of the most widely accepted appraisal instruments in medicine, AGREE-II and the RIGHT statement, in a blinded and anonymous process designed to eliminate bias between raters.

The panel itself was deliberately unconventional. Alongside neonatologists with at least a decade of experience in academic cooling centres, it included a paediatric intensivist, an obstetrician and an adult intensivist, reflecting the perinatal origins of the condition and the broader critical care experience with temperature control. None of the raters had been involved in producing any of the guidelines under scrutiny, and each evaluated the documents without knowing how their colleagues had scored them. Inter-rater agreement was strong, with intraclass correlation coefficients of 0.831 for quality and 0.909 for reporting completeness, lending statistical weight to the consensus findings.

The results were striking. On the AGREE-II instrument, which assesses six domains including purpose, stakeholder involvement, rigour of development, clarity, applicability and editorial independence, the German guidelines scored highest overall and were judged to be of medium quality, while the Norwegian guidelines scored lowest. But the most damning finding concerned the domain widely regarded as the most important: rigour of development. Not a single guideline achieved a high score here, and even the German document fell short of the fifty per cent mark. In practical terms, this means that none of the eleven documents demonstrated a transparent, systematic process for searching, appraising and grading the underlying evidence.

Reporting completeness, measured with the RIGHT statement across seven domains and thirty-seven items, was equally troubling. Total completeness ranged from just twenty to forty-nine per cent, and no guideline achieved satisfactory global completeness. The French guidelines performed best at the domain level, while the Swiss guidelines fared worst. Many guidelines lacked even basic information: most did not state whether they had undergone peer review, and the majority were silent on their consensus methodology and on how recommendations were graded. Only the French and Italian guidelines had been published in full as peer-reviewed articles, which the authors suggest may partly explain the generally moderate-to-low quality of documents that never faced academic scrutiny.

Beneath the methodological scores lie clinically consequential discrepancies. The guidelines disagree on the very thresholds used to decide which babies should be cooled, prescribing different cut-offs for base excess, pH and lactate, with some even advising clinicians not to trust cord blood gas values. They weigh the neurological examination differently, giving variable importance to the components of the Sarnat score or substituting different scoring systems, and they interpret amplitude-integrated EEG findings in inconsistent ways. These are not academic quibbles: the eligibility decision determines whether a newborn receives a complex, resource-intensive therapy that can alter the trajectory of an entire life.

The inconsistencies widen sharply in the grey areas that clinicians encounter daily. For late preterm infants, recent randomised trial data suggest that cooling may be associated with white matter injury and increased likelihood of death or disability, yet the guidelines offer divergent and weakly supported advice. For babies transferred to a referral centre after the crucial first six hours of life, a common scenario depending on geography and transport logistics, evidence suggests cooling may still help, but guidance again varies. Alarmingly, none of the eleven documents addressed the use of therapeutic hypothermia in babies requiring extracorporeal life support, leaving an entire category of the sickest patients without any documented direction.

The authors argue that this heterogeneity cannot be explained by the evidence itself, because the original randomised trials that established the therapy’s effectiveness used essentially similar inclusion criteria. Instead, local custom and differing interpretations have accumulated into recommendations that were never tested in dedicated trials. The consequences ripple outward: patients receive different care depending on where they are born, intensive care beds and healthcare costs are affected, and medico-legal exposure grows when practice diverges between centres and countries for reasons that the available evidence does not justify. The American Academy of Pediatrics has meanwhile reaffirmed that cooled newborns should meet the inclusion criteria of the published trials, underscoring how far some European documents have drifted.

The study team is careful to acknowledge its limits. The sample was a convenience set of guidelines from countries with the largest ESPNIC membership and does not cover every European nation, and healthcare organisation, reimbursement and regionalisation differ across jurisdictions in ways that may shape national documents. Still, the central message is unambiguous: no guideline evaluated should be applied directly without critical appraisal and modification. The authors call for national bodies, or better still continental organisations, to rebuild neonatal cooling guidance using the strict methodological standards already adopted in adult critical care medicine, and to commission studies in the grey areas where evidence is thin.

For clinicians at the bedside, the findings are a call to scepticism rather than despair. Therapeutic hypothermia remains firmly evidence-based and profoundly valuable, but the documents that translate that evidence into practice have not kept pace with the standards the field now demands. Reading guidelines critically, understanding where they rest on solid trials and where they rest on local habit, may be the most important skill a neonatal intensivist can bring to the cooling cot, at least until Europe’s next generation of guidelines earns the trust that babies and their families deserve.

Subject of Research: Quality and completeness of European clinical practice guidelines for neonatal therapeutic hypothermia

Article Title: Clinical practice guidelines for neonatal therapeutic hypothermia across European Society for Paediatric and Neonatal Intensive Care (ESPNIC) member countries: a multidisciplinary blind comparison

Article References: De Luca, D., Neri, C., Alonso-Ojembarrena, A., Ippolito, M., Milan, A., Piastra, M., Sanchez-Luna, M., Schettler, K. F., Zanin, A., Ghi, T., & Cortegiani, A. (2026). Clinical practice guidelines for neonatal therapeutic hypothermia across European Society for Paediatric and Neonatal Intensive Care (ESPNIC) member countries: a multidisciplinary blind comparison. The Lancet Regional Health – Europe, 71, Article 101874. https://doi.org/10.1016/j.lanepe.2026.101874

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101874

Keywords: therapeutic hypothermia, neonatology, hypoxic-ischaemic encephalopathy, clinical practice guidelines, ESPNIC, AGREE-II, RIGHT statement, guideline quality, perinatal asphyxia, neonatal intensive care, Europe, evidence-based medicine